OSE Immunotherapeutics SA, a biotech startup, was selected by Microsoft France to be a partner of its support program for French Biotech & Deeptech Startups, which aims to support companies at the crossroads of research and technology to accelerate discovery and development. This program provides the selected startups with technical support to develop a technical framework of architecture securing scalability and startups’ data security. It also proposes a business support from Microsoft France and its partners through an ecosystem approach connecting startups, the research community, investment funds and the various health players.
 
Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, said, “We are very happy to have been selected by Microsoft to join their Biotech & Deeptech support program and we warmly thank the organizers. This collaboration confirms that OSE perfectly fits the target of the most cutting-edge biotechs by pairing its scientific skills and expertise in artificial intelligence and algorithmic approach to develop immunotherapies based on breakthrough innovations and to meet unmet medical needs in immuno-oncology and immuno-inflammation.”
 
OSE Immunotherapeutics has been collaborating with MAbSilico, a DeepTech-Bio company specializing in artificial intelligence (AI) algorithms and machine learning to accelerate the research and characterization of therapeutic antibodies.
 
Since 2021, OSE has benefitted from access to the MAbFactory platform which centralizes MAbSilico’s  solutions based on AI. MAbFactory is deployed in the Microsoft Azure cloud with the access to an automatic and autonomous use to support the development of new antibodies and therapeutic proteins. The expertise of OSE’s R&D teams combined with MAbSilico’s AI platform is being used to guide the discovery, the characterization and the optimization of new molecules, with the goal of reducing both development time and the risk of failure in preclinical testing.